| abstract |
The invention relates to CGRP antagonists of general formula (I), in which R<SUP>1</SUP>, R<SUP>2</SUP>, R<SUP>3</SUP> and R<SUP>4</SUP> are described in Claim 1, to the tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and salts thereof, to the hydrates of the salts, particularly their physiologically compatible salts with inorganic or organic acids or bases, to the compounds of general formula (I), in which one or more hydrogen atoms are exchanged for deuterium, to medicaments containing these compounds, the use thereof, and to methods for producing them. |